As a developer of antisense-based cancer treatments, OncoGenex was naturally interested in RNA interference when it came onto the scene. But despite having significant success using RNAi for target validation work, the company decided the gene-silencing technology was not quite ready for therapeutic applications, and opted for a next-generation antisense approach in its latest drug program.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.